MINUTES OF MEETING

Date: Thursday, June 15, 2017

Time: 9:00 a.m.

Place: Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Members Present: Kerri Okamura, RPh, Chair, Pharmacist
Garrett Lau, RPh, Vice Chair, Pharmacist
Julie Takishima-Lacasa, PhD, Public
Mary Jo Keefe, RPh, Pharmacist
Ronald Weinberg, Public
Marcella Chock, PharmD., Pharmacist
Carolyn Ma, PharmD., BCOP, Pharmacist

Staff Present: Lee Ann Teshima, Executive Officer ("EO")
Lisa Kalani, Secretary

Guests: Dean Yamamoto, Dept. of Public Safety Narcotics Enforcement Division
Jennifer Fujio, Daniel K. Inouye, College of Pharmacy
Paul Smith, Walgreens
Fred Cruz, CVS Caremark
Tiffany Yajima, Ashford & Wriston LLP
Stacy Pi, Kaiser Permanente
Catalina Cross, Times
Patrick Uyemoto, Times
Joe Parrott, Walmart
Alanna Isobe, Safeway
Jon Cheng, Kaiser Permanente

Call to Order: The agenda for this meeting was filed with the Office of the Lieutenant Governor, as required by section 92-7(b), Hawaii Revised Statutes ("HRS").

There being a quorum present, the Chair called the meeting to order at 9:03 a.m.
Chair's Report:

Announcements and Introductions

The Chair announced that after serving two full terms, today is the Vice Chair Garrett Lau's last meeting. She presented him with a lei and certificate of appreciation on behalf of the Board and a letter and certificate of appreciation on behalf of the Professional & Vocational Licensing Division.

The Chair asked the audience to introduce themselves.

Approval of the Previous Minutes – May 18, 2017 Meeting

The Chair called for a motion in regards to the minutes of the May 18, 2017 meeting.

The Chair stated on page 7, 8th paragraph starting with “Mr. Redulla stated”, she was unclear what was meant by “…NED does mind the PDMP data…”.

The EO asked Mr. Yamamoto if they monitor the PDMP?

Mr. Yamamoto stated the data is reported to their office on a required basis. It remains there until an investigation is open or something needs to be done to look at it. There is no one actively looking at it.

Dr. Takishima-Lacasa asked if he would say they maintain it?

Mr. Yamamoto replied yes, you could say that we maintain it.

The EO stated we will amend the minutes to read, “Mr. Redulla stated NED maintains the PDMP data…”.

There being no further discussion, upon a motion by Mr. Weinberg, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the minutes for the May 18, 2017 meeting as amended.

Executive Officer's Report:

Conferences/Seminars/Meetings


Ms. Keefe provided a written report to the Board. Some issues/topics from the meeting were as follows:

- According to USP, 80% of medication ingredients come from overseas;
- Antibacterial resistance can be attributed, in part, to substandard medications;
- Drugs imported from Canada increases patient risk without guarantee of lower prices;
• Expanding technician roles to allow expanded pharmacist roles;
• Staffing ratios – 19 states have them varying from 1 to 6, NABP Model Rules have no ratio;
• Texting prescriptions;
• Ticketing vs. Citations – tickets are not considered discipline;
• Specialty Pharmacy – The future of Pharmacist care;
• Telehealth; and
• Naloxone and Beyond: Can expanded scopes impact the Opioid Epidemic.

Ms. Keefe brought her book from the meeting and offered it for review and also stated that everything from the meeting is posted on the NABP website and encourages everyone to view it.

NABP-AACP District 6-7-8 Annual Meeting, October 8-11, 2017, San Antonio, Texas
The EO asked if anyone was interested in attending to let her know. We will try to have the Department pay for the registration.

2017 Legislative Session

The EO reported the following bills are currently at the Governor’s office awaiting his approval/veto:

➢ SB 514, SD1, HD1 Relating to Health (HPV)
➢ SB 513, SD1, HD2 Relating to Contraceptive Supplies
➢ HB 1444, HD2, SD2 Relating to Pharmacy Benefit Managers
➢ SB 505, SD1, HD2 Relating to Health (Informed consent to opioid therapy)
➢ SB 997, SD1, HD2 Relating to the Uniform Controlled Substances Act

Dr. Ma clarified that the bills could go through even if he does not sign them?

The EO stated correct, as long as they are not on his veto list.

➢ HCR 164, SD1 Requesting That the Director of Health Establish and Convene a Medication Synchronization Working Group to Explore and Propose Legislation
The EO reported that the first meeting will be June 21, 2017, and she will be attending.

Naloxone Collaborative Practice

Report/Minutes on the May 18, 2017 Working Group Meeting
At the Working Group’s first meeting last month, they discussed:

➢ Mandatory criteria for collaborative practice agreement;
➢ Standing orders;
➢ Approved training; and
➢ Reimbursement.
The following members of the Working Group will be meeting immediately after the Board meeting today:

- Kerri Okamura, BOP Chair
- Garrett Lau, BOP Vice Chair
- Fred Cruz or representative from CVS
- Paul Smith, Pharmacist
- Patrick Uyemoto, HPhA
- Stacy Pi, Kaiser
- Joe Parriott, Walmart
- Tiffany Yajima, Walgreens
- Peter Whiticar or representative from Department of Health (DOH"
- Keri Oyadomari or representative from 5-Minute Pharmacy
- Representative from Narcotics Enforcement Division
- Lee Ann Teshima, Executive Officer for the Board of Pharmacy
- Heather Lusk, The CHOW Project

Department of Public Safety, Narcotics Enforcement Division ("NED") - Presentation on Statutory Requirements of Reporting Theft/Missing Controlled Substances and NED Reporting Form.

Mr. Yamamoto provided the Board with an Information Sheet and copy of a Controlled Substance Incident Report form and a Controlled Substance Inventory form. Mr. Yamamoto cited some key components from the Information Sheet as follows:

- **Examples of Reportable Theft or Loss**
  Any diversion, theft, burglary, missing inventory, missing drugs during counts, damaged stock resulting in missing/unaccounted for controlled substances;

- **State Law Hawaii Administrative Rule 23-200-12**
  Theft or Loss must be reported to the Narcotics Enforcement Division ("NED") within 24 hours of having actual knowledge of theft or loss of controlled substances. Furthermore, a written report must be submitted to the NED within three business days;

- **Federal Law 21CFR 1376.1**
  Any Theft and any SIGNIFICANT loss must be reported to the local DEA field office within one business day. “Significant” depends on many factors (Note: Best to report ANY theft/loss);

- **How to Report**
  State reporting requirements: within 24 hours – phone call to the NED office (808) 837-8470 or after hours (808) 363-0576. Within 3 business days – submit NED form “Controlled Substances Incident Report”, or submit completed copy of DEA Form 106, or write a detailed letter explaining the facts and circumstances surrounding the theft or loss of controlled substances including who, what, where, when, how and why.

  DEA reporting requirements: within one business day, go to website: deadiversion.usdoj.gov. Look for forms and electronically fill out DEA Form-106. Print a copy for your records.; and
• Violations for Non-Reporting

Violation for non-reporting of theft and loss of controlled substances can be treated as a felony under State Law. Furthermore, both the NED and DEA may take action against the registrant’s controlled substance registration.

Dr. Chock asked if the Controlled Substances Incident Report form can be used for the 24 hours reporting or the 3 days, and can the 24 hours report be verbal?

Mr. Yamamoto replied the form can be used for both. The 24 hours report can be verbal, however, the report that has to be filed within 3 days must be in writing.

Mr. Weinberg asked what if a consumer picks up his pills, takes them home, and then discovers some are missing, can that be reported?

Mr. Yamamoto stated you would want to contact the pharmacy that filled that prescription. If it is determined it’s a misfill by the pharmacy, that is considered a missing controlled substance and needs to be reported by the pharmacy that filled the prescription.

The EO asked if Wholesale Distributor’s get investigated as well?

Mr. Yamamoto replied yes, and if it is interstate we would work together with the DEA.

Correspondence:

National Association of Boards of Pharmacy – May 2017 State News Roundup

The Chair asked the Vice Chair to lead the discussion on the following:

Delaware Opioid Analgesics Prescribing Regulations Take Effect
Safe prescribing of opioid analgesics regulations went into effect in Delaware on April 1, 2017. Some of the new regulations are as follows:
- Substance Use Disorder Evaluation Tool;
- Quantity Limits on Prescriptions on Acute Episode of Pain; and
- Elements for Chronic Long-Term Treatment of Pain;

Ohio Authorizes the Dispensing of Multiple Simultaneous Refills on Prescriptions
Effective April 6, 2017, Section 4729.40 of the Ohio Revised Code authorizes a pharmacist who is filling or refilling a prescription that has one or more refills to dispense the drug in a quantity or amount that varies from the quantity or amount that would otherwise be dispensed. This authority is contingent on meeting conditions specified in the law, including conditions concerning the quantity or amount that may be dispensed and the type of drug prescribed.

The Vice Chair stated he checked Ohio’s webpage and this new law does not apply to controlled substances.
Ohio Sets New Limits on Prescription Opiates for Acute Pain
On March 30, 2017, new limits were announced on prescription opiate prescribing. The limits will place commonsense parameters on the use of opiates for the treatment of acute pain. Based on data from the Ohio Automated Rx Reporting System, it is estimated that the state could see an additional reduction of 109 million opiate doses once the new rules are in effect.

The limits are not currently effective and must be adopted by the Ohio medical, nursing, and dental boards through the administrative rules process.

Oregon Introduces Online Pharmacist-in-Charge Change Forms
The Oregon State Board of Pharmacy is no longer accepting emailed, mailed, or faxed pharmacist-in-charge (PIC) change forms. Reporting of a PIC change must be done via online submission. Both incoming and outgoing PICs must fill out their corresponding forms, and all required fields must be filled in when submitting the forms.

Resident Pharmacy Outlets Required to Submit Termination Reports in Oregon
Effective February 23, 2017, a resident pharmacy outlet that terminates or allows an Oregon State Board of Pharmacy licensee to resign in lieu of termination must report the termination or resignation to the Board within 10 working days. The Board requests that the report include if the termination was due to a suspected violation.

Utah 2017 Legislature Passes Pharmacy-Related Bills
The Utah State Legislature passed the following pharmacy-related bills in its 2017 General Session:

- **House Bill 61**: Pharmacy Service for Discharged Hospital Patients - Allows a hospital pharmacy to dispense a limited supply of a prescription drug to a discharged patient under certain circumstances when the patient’s regular retail pharmacy is not available.

- **Senate Bill 246 1 Sub**: Pharmacy Practice Act Amendments - Amends the Pharmacy Practice Act. Specifically, it requires certain Utah-licensed nonresident pharmacies to submit to an inspection as a prerequisite for licensure, excludes drugs administered under certain conditions from certain drug-container labeling requirements, and permits certain pharmacists to administer long-acting injectable drugs intramuscularly under certain conditions.

Pharmacy Receiving Drug Samples
The Chair asked Dr. Chock to lead the discussion on the following email inquiry:

“I’m a pharmacist that oversees an Inpatient Psychiatric unit. A few drug company representatives have been promoting a free trial program for long-acting injectable antipsychotic agents. Could you please tell me if this is permissible by law?”
I have a concern about us (pharmacists) handling drug samples. While these products are not labeled as samples, it seems that these products are still legally considered samples based on the definition of “a unit of a prescription drug that is not intended to be sold and is intended to promote the sale of the drug” found in the Prescription Drug Marketing Act (21 CFR § 203.3).”

Dr. Chock stated these products are commercially labeled as a trade product, not a sample product.

The Board after a brief discussion and a review of the laws and rules and the Prescription Drug Marketing Act cited in the email and according to the information contained in the Inpatient Hospital Pharmacy Free Trial Program, the product in question is not labeled as a sample product.

Consequently, the Board by consensus determined that since this was not considered a drug sample and if the drug is ordered by a physician, a pharmacy could acquire the drug to be dispensed.

In accordance with Hawaii Administrative Rules section 16-201-90, the above interpretation is for informational and explanatory purposes only. It is not an official opinion or decision and is thus, not binding on the Board. If you wish to obtain a formal opinion, you must submit a Petition for Declaratory Relief to the Board.

“The Addicts Next Door” an Article from The New Yorker

The Chair asked Ms. Keefe to lead the discussion an article from The New Yorker titled “The Addicts Next Door”. The article touches on the state of West Virginia and in one excerpt it reads, “At this state of the American opioid epidemic, many addicts are collapsing in public gas stations, in restaurant bathrooms, in the aisles of big-box stores.” It goes on to say, “West Virginia has the highest overdose death rate in the country, and heroin has devastated the state’s Eastern Panhandle, which includes Hedgesville and the larger town of Martinsburg. Like the vast majority of residents there, nearly all the addicts are white, were born in the area, and have modest incomes. In Berkeley County, which has a population of a hundred and fourteen thousand, when someone under sixty dies, and the cause of death isn’t mentioned in the paper, locals assume that it was an overdose.” The writer of the article rode with this paramedic, and so the article is about his days of being a paramedic and saving all these people in this area. It is a long, but very interesting read.
Pharmacists Administering Medications Via Ventrogluteal Route

The Chair called upon Ms. Isobe to address the Board on her email requesting for clarification regarding medication administration. Ms. Isobe wrote to the Board on behalf of Albertsons Companies, which operates 11 Safeway Pharmacies in the state of Hawaii, to request approval to allow properly trained pharmacists to administer medications via the ventrogluteal (VG) route. The VG training program is provided by a division of ventrogluteal administration trainer or a contracted nurse who first teaches the VG administration technique and then witnesses the student’s first administration.

The EO asked what the ventrogluteal route is?

Dr. Ma replied it is into the hip muscle.

Dr. Chock asked about the setting. This particular site would require a bit more privacy. Are retail pharmacies set up for this?

Ms. Isobe replied that each pharmacy would have to use their own discretion.

The Chair stated under the definition of “Practice of pharmacy” in Chapter 461 it states, (D) Administering drugs orally, topically, by intranasal delivery, or by injection, pursuant to the order of the patient’s licensed physician or advanced practice registered nurse with prescriptive authority, by a pharmacist having appropriate training that includes programs approved by the ACPE, curriculum-based programs from an ACPE-accredited college of pharmacy, state or local health department programs, or programs recognized by the board of pharmacy. So it would appear the administration falls under the definition, however you understand the training requirements, and that would be part of the question whether or not it would be approved by the Board. Is it ACPE approved training?

Ms. Isobe stated their pharmacists have done ACPE immunization training, and this is the same technique just on a different site, are we doing training for each site separately?

Dr. Chock stated APhA is very specific in that with that training, it is only for the deltoid with intra-muscular. They do understand that there are other sites, but they do not include those sites for the purpose that the training is much more involved.

The EO stated the practice act does not prohibit any specific injection site. It is basically based on the training that the pharmacist receives. Therefore, if a pharmacist wants to do this, then they have to receive the appropriate training and education.

Dr. Ma stated that if Albertsons training could get ACPE approved then it would be acceptable. Or, if the Board wants to look at the training program to see if we can recognize it.
The EO asked if the Board could receive more information on the training program, like the curriculum, course descriptions, etc., then the they could review it.

Ms. Isobe stated she will get that information to the Board.

**Executive Session:**

At 10:30 a.m. upon a motion by Dr. Ma, seconded by Ms. Keefe, it was voted on and unanimously carried to move into Executive Session in accordance with HRS, 92-5(a)(4), “To discuss applications and issues pertaining to the board’s powers, duties, privileges, immunities, and liabilities”.

At 10:47 a.m. upon a motion by Dr. Chock, seconded by Dr. Takishima-Lacasa, it was voted on and unanimously carried to move out of executive session.

**Chapter 91, HRS,**

**Adjudicatory Matters:**

The Chair called for a recess from the meeting at 10:47 a.m. to discuss and deliberate on the following adjudicatory matter(s) pursuant to Chapter 91, HRS:

In the Matter of the Wholesale Prescription Drug Distributor License of **Owens & Minor Distribution, Inc.; PHA 2017-13-L,** Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Pharmacist's License of **Gregory Kavadias; PHA 2014-25-L,** Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Soleo Health; PHA 2017-15-L,** Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibits “1” through “5”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Wells Pharmacy Network, LLC; PHA 2016-30-L,** Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibits “1” through “3”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.
In the Matter of the Miscellaneous Permit of **OptumRx, Inc. dba Optum Rx; PHA 2017-12-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Promesa Health, Inc.; PHA 2017-40-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Civic Center Pharmacy; PHA 2017-16-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Palm Beach Pharmaceuticals, Inc.; PHA 2017-11-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Diamond Drug, Inc., dba Diamond Pharmacy Services; PHA 2017-21-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of **Enclara Pharmacia, Inc., fka Excellerx, Inc.; PHA 2014-1-L**, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibits “1” through “12”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.
In the Matter of the Miscellaneous Permit of Revival Animal Health; PHA 2017-36-L, Settlement Agreement Prior to Filing of Petition for Disciplinary Action and Board’s Final Order; Exhibit “1”

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Final Order.

In the Matter of the Miscellaneous Permit of College Pharmacy, Inc., dba College Pharmacy, Board of Pharmacy’s Proposed Order.

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the Board’s Proposed Order.

Following the Board’s review, deliberation, and decisions in this matter, pursuant to Chapter 91, HRS, the Chair announced that the Board was reconvening its scheduled meeting at 10:54 a.m.

Applications:

Ratification List

Upon a motion by Mr. Weinberg, seconded by Dr. Chock, it was voted on and unanimously carried to approve the attached ratification lists.

Pharmacist

Upon a motion by the Chair, seconded by the Vice Chair, it was voted on and unanimously carried to issue a conditional license upon passage of the Hawaii MPJE and payment of any applicable license fees. Conditions are as follows:

- may not be a pharmacist-in-charge while practicing in Hawaii;
- may not work in a pharmacy in Hawaii without another pharmacist on duty; and
- may not have access to any controlled substances while working in a pharmacy.

Thomas Hite

Upon a motion by the Chair, seconded by the Mr. Weinberg it was voted on and unanimously carried to approve the following:

Kris Kim
Janice C. Flynn

Miscellaneous Pharmacy Permits (PMPs)

Upon a motion by the Chair, seconded by Dr. Chock, it was voted on and unanimously carried to approve the following:

Talca Pharmaceuticals Inc. - Kenneth J. Amodeo
Prime Therapeutics Specialty Pharmacy LLC (PMP 1407) - Jasmine M. Vu
Wholesale Prescription Drug Distributor
Upon a motion by the Chair, seconded by Ms. Keefe, it was voted on and unanimously carried to approve the following

Medline Industries, Inc.

Next Meeting:  The Chair announced that the next Board meeting is scheduled for Thursday, July 20, 2017.

The Chair, Dr. Chock, Dr. Ma and Ms. Keefe stated they cannot attend the July 20th meeting.

The Chair stated the July 20th meeting is cancelled due to no quorum and announced the next Board meeting is scheduled for Thursday, August 17, 2017.

Thursday, August 17, 2017
9:00 a.m.
Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Adjournment:  With no further business to discuss, the Chair adjourned the meeting at 11:00 a.m.

Taken and recorded by:  Reviewed and approved by:

/s/ Lisa Kalani  /s/ Lee Ann Teshima
Lisa Kalani, Secretary  Lee Ann Teshima, Executive Officer

6/29/17

[  ] Minutes approved as is.
[X] Minutes approved with changes; see minutes of 8/17/17
Miscellaneous Permits (PMP)

Change of PIC

**Integrated Health Concepts Inc. dba Conversio Health (PMP-887)**
720 Aerovista Pl. Ste. D
San Luis Obispo, CA. 93401
New PIC: Sabrina Rodriguez
Effective: 5/11/17

**Tomeldon Co Inc. dba Pharmacy Solutions (PMP-921)**
1921 W Pioneer Pkwy.
Arlington, TX. 76013
New PIC: Christopher Lloyd
Effective: 5/1/17

**Coast Quality Pharmacy LLC (PMP-1079)**
5710 Hoover Blvd.
Tampa, FL. 33634
New PIC: Dennis Davis
Effective: 5/17/17

**Kroger Specialty Infusion CA (PMP-1331)**
19110 Van Ness Ave.
Torrance, CA. 90501
New PIC: Kirankumar Patel
Effective: 5/19/17

Closure/Cancellation

**Dena Group Inc. dba Alpha Pharmacy (PMP-1160)**
8787 N Macarthur Blvd. #120
Irving, TX. 75063
Effective: 5/18/17

Relocation/Address Change

**Nufactor Inc. (PMP-248)**
44900 Winchester Rd.
Temecula, CA. 92590
Effective: 6/2/17

**Patient Services & Solutions Inc. dba Shared Solutions Pharmacy (PMP-843)**
4500 W 107th St.
Overland Park, KS. 66207
Effective: 5/15/17
Pharmacy (PHY)

Change of PIC
QSI Inc. dba Times Pharmacy #11 (PHY-628)
1425 Liliha St.
Honolulu, HI 96817
New PIC: Rayanne Pascua
Effective: 5/1/17

QSI Inc. dba Times Pharmacy #25 (PHY-886)
1620 N School St.
Honolulu, HI 96817
New PIC: Arthur Lush
Effective: 5/1/17

Wahiawa Gen Hosp dba Wahiawa Gen Hosp PHY (PHY-183)
128 Lehua St.
Wahiawa, HI 96786
New PIC: Carol Parker
Effective: 5/17/17

Wholesale Distributor

Closure/Cancellation
Owens & Minor Distribution Inc. (PWD-126)
91-240 Kalaeloa Blvd.
Kapolei, HI 96707
Effective: 1/1/17
RATIFICATION LIST 6/15/17

PHARMACIST

PH 4164 JEAN M <RILEY>
PH 4165 JOSEPH J <FREDRICK>
PH 4166 TIEN M <TRUONG>
PH 4167 ROBERT B <DOBBINS>
PH 4168 MITAL <PATEL>
PH 4169 CHRISTOPHER G <WILSON>
PH 4170 LAURA M <WATKINS>
PH 4171 KERIANN M <BENNETT>
PH 4172 AMANDA E <DARGUSH>
PH 4173 JANICE A <HAVLIK>

PHARMACY

PHY 914 710 N KING ST HONOLULU HI 96817 KALIHI-PALAMA HEALTH CENTER

MISCELLANEOUS PERMIT

PMP 1406 7265 S REVERE PKWY STE 902 CENTENNIAL CO 80112 CANYON MEDICAL PHARMACY INC
PMP 1407 2901 KINWEST PKWY STE 250 IRVING TX 75063 PRIME THERAPEUTICS SPECIALTY PHARMACY LLC
PMP 1408 4802 N SAM HOUSTON PKWY #100 HOUSTON TX 77086 VETERINARY PHARMACIES OF AMERICA LLC
PMP 1409 1608 ROUTE 88 #120 BRICK NJ 08724 TOPS PHARMACY INC
PMP 1410 9150 SW PIONEER CT STE F WILSONVILLE OR 97070 SPECIALTY COMPOUNDING PHARMACY LLC
PMP 1411 4338 E 142ND ST GRANDVIEW MO 64030 HEART OF AMERICA PHARMACY LLC
PMP 1412 3793 S STATE ST SALT LAKE CITY UT 84115 BYRAM HEALTHCARE CENTERS INC